SCHEMBL1367500

SCHEMBL1367500

CC(Sc1cccc(-c2ccc(C(=O)Nc3ccc(Cl)c(C(=O)Nc4cnc5[nH]ccc5c4)c3)cc2)c1)C(N)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 5/20 0.50
TNIK Q9UKE5 1/20 0.42
PIK3CA P42336 2/20 0.42
MTOR P42345 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PDGFRB P09619 2/20 0.40
CSF1R P07333 2/20 0.40
JAK2 O60674 1/20 0.40
FGFR1 P11362 1/20 0.40
CYP2C9 P11712 1/20 0.40
EPHB4 P54760 1/20 0.40
PTK2 Q05397 1/20 0.40
MAPK14 Q16539 1/20 0.40
CDK8 P49336 7/20 0.40
CDK7 P50613 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1366577 0.84 BRAF (0.60) BRAFTNIKPIK3CAMTORKDM4E
SCHEMBL1365186 0.81 BRAF (0.59) BRAFTNIKKDM4EMEN1LMNA
SCHEMBL1367636 0.77 BRAF (0.52) BRAFTNIKKDM4EMEN1LMNA
SCHEMBL1367193 0.74 BRAF (0.56) BRAFTNIKPIK3CAMTORKDM4E
SCHEMBL4107604 0.74 BRAF (0.61) BRAFPIK3CAMTORCDK8CDK7
SCHEMBL1367889 0.74 BRAF (0.59) BRAFTNIKPIK3CAMTORCSF1R
SCHEMBL1367284 0.73 BRAF (0.60) BRAFPDGFRBCSF1RJAK2FGFR1
SCHEMBL4478587 0.72 TNK2 (0.54) PDGFRBFGFR1EPHB4FESPDGFRA
SCHEMBL1366062 0.71 BRAF (0.62) BRAFTNIKPIK3CAMTORKDR
SCHEMBL1369057 0.71 BRAF (0.62) BRAFTNIKPIK3CAMTORKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067599-B2 Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors HOFFMAN-LA ROCHE INC. (US) 2011-11-29 US claimed
US-20090318428-A1 HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS HOFFMANN-LA ROCHE, INC. 2009-12-24 US claimed
US-8067599-B2 Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors HOFFMAN-LA ROCHE INC. (US) 2011-11-29 US disclosed
US-20090318428-A1 HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS HOFFMANN-LA ROCHE, INC. 2009-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318428-A1 HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS MAP3K5, MAP3K1, PRKACA BRAF 35/4885TNIK 257/4885PIK3CA 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.